文献速递神经免疫

复发型多发性硬化口服免疫调节治疗进展

Advances in oral immunomodulating therapies in relapsing multiple sclerosis.
PubMed 文献 · Lancet Neurol · 2020-02-11

本文综述复发型多发性硬化口服免疫调节治疗的进展。已获批的口服药物包括芬戈莫德、富马酸二甲酯、特立氟胺和克拉屈滨,新药如西尼莫德、奥扎尼莫德、米诺环素、evobrutinib等正在研发或审批中。文章强调需平衡疗效与风险,并关注序贯治疗的长期安全性。

要点

  • 口服药物作用机制不同,可根据合并症个体化选择。
  • 西尼莫德已获FDA批准用于复发型多发性硬化包括活动性继发进展型。
  • 序贯单药治疗可能产生类似联合治疗的累积效应,需长期监测安全性。

核心结论

  • 口服免疫调节治疗显著扩展了复发型多发性硬化的治疗选择,但需平衡疗效与风险并关注序贯治疗的长期安全性。

研究设计与样本

  • 本文为综述,总结了已获批口服药物及在研新药的作用机制与临床试验结果。

主要发现

  • 西尼莫德于2019年3月获FDA批准用于复发型多发性硬化包括活动性继发进展型。
  • 奥扎尼莫德在两项3期试验中降低复发率和MRI活动。
  • 米诺环素减少临床孤立综合征患者转化为多发性硬化。
  • Evobrutinib在2期试验中降低MRI活动,3期试验正在进行。
  • Diroximel fumarate旨在改善胃肠道耐受性,正在测试中。

关键数值与推荐

  • 已获批口服药物包括芬戈莫德、富马酸二甲酯、特立氟胺和克拉屈滨。
  • 西尼莫德靶向S1PR1和S1PR5,于2019年3月获FDA批准。
  • 奥扎尼莫德靶向S1PR1和S1PR5,处于审批阶段。
  • Laquinimod在3期试验中未达到确认残疾进展减少的主要终点。
  • Laquinimod在原发性进展型多发性硬化2期试验中未达到脑体积损失减少的主要终点。

临床怎么用

  • 根据个体合并症和药物作用机制选择口服治疗。
  • 关注序贯治疗的累积免疫效应,监测短期和长期安全性。

局限性

  • 序贯治疗在2期和3期试验中大多被排除,需4期研究、队列研究和登记研究监测长期效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oral treatment options for disease-modifying therapy in relapsing multiple sclerosis have substantially increased over the past decade with four approved oral compounds now available: fingolimod, dimethyl fumarate, teriflunomide, and cladribine. Although these immunomodulating therapies are all orally administered, and thus convenient for patients, they have different modes of action. These distinct mechanisms of action allow better adaption of treatments according to individual comorbidities and offer different mechanisms of treatment such as inhibition of immune cell trafficking versus immune cell depletion, thereby substantially expanding the available treatment options. RECENT DEVELOPMENTS: New sphingosine-1-phosphate receptor (S1PR) modulators with more specific S1PR target profiles and potentially better safety profiles compared with fingolimod were tested in patients with relapsing multiple sclerosis. For example, siponimod, which targets S1PR1 and S1PR5, was approved in March, 2019, by the US Food and Drug Administration for the treatment of relapsing multiple sclerosis including active secondary progressive multiple sclerosis. Ozanimod, another S1P receptor modulator in the approval stage that also targets S1PR1 and S1PR5, reduced relapse rates and MRI activity in two phase 3 trials of patients with relapsing multiple sclerosis. Blocking of matrix metalloproteinases or tyrosine kinases are novel modes of action in the treatment of relapsing multiple sclerosis, which are exhibited by minocycline and evobrutinib, respectively. Minocycline reduced conversion to multiple sclerosis in patients with a clinically isolated syndrome. Evobrutinib reduced MRI activity in a phase 2 trial, and a phase 3 trial is underway, in patients with relapsing multiple sclerosis. Diroximel fumarate is metabolised to monomethyl fumarate, the active metabolite of dimethyl fumarate, reduces circulating lymphocytes and modifies the activation profile of monocytes, and is being tested in this disease with the aim to improve gastrointestinal tolerability. The oral immunomodulator laquinimod did not reach the primary endpoint of reduction in confirmed disability progression in a phase 3 trial of patients with relapsing multiple sclerosis. In a phase 2 trial of patients with primary progressive multiple sclerosis, laquinimod also did not reach the primary endpoint of a reduction in brain volume loss, as a consequence the development of this drug will probably not be continued in multiple sclerosis. WHERE NEXT?: Several new oral compounds are in late-stage clinical development. With new modes of action introduced to the treatment of multiple sclerosis, the question of how to select and sequence different treatments in individual patients arises. Balancing risks with the expected efficacy of disease-modifying therapies will still be key for treatment selection. However, risks as well as efficacy can change when moving from the controlled clinical trial setting to clinical practice. Because some oral treatments, such as cladribine, have long-lasting effects on the immune system, the cumulative effects of sequential monotherapies can resemble the effects of a concurrent combination therapy. This treatment scheme might lead to higher efficacy but also to new safety concerns. These sequential treatments were largely excluded in phase 2 and 3 trials; therefore, monitoring both short-term and long-term effects of sequential disease-modifying therapies in phase 4 studies, cohort studies, and registries will be necessary.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Derfuss T, Mehling M, Papadopoulou A, et al. Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol. 2020. PMID: 32059809. doi:10.1016/S1474-4422(19)30391-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。